MBA Summer Associate
Posted on: 24 Mar 2021
Cambridge, MA
Job Description
Objective is to drive development and execution of HCP experience at the Respiratory businesses’ largest medical convention (ERS) and beyond.
Background
During COVID, all medical conventions converted to an on-line digital presence. Sanofi initiated work streams to ensure we are fully capitalizing on this changing environment. During 2021, expectations for content delivery and quality are projected to increase. In order to remain in the leadership spot, we have to ensure a more comprehensive offering fully utilizing multi-channel capabilities targeted to our largest convention of the year
Specific tasks include
analyze insight and data on customer behavior during digitally-delivered medical conventions in 2020/2021
link with adjacent workstreams in HCP & Peer-to-Peer marketing, Digital excellence teams, Medical team, Communication & Convention teams
research insights from within the industry and adjacent industries to help develop specific tactics
work within the marketing team to champion convention-related customer experience
gather and synthesize information from these internal stakeholders and external stakeholders (data vendors, Alliance partner, HCP, agencies)
Key deliverable is a presentation to Global Brand Team covering hypotheses and recommendations, as well as timeline and implementation plan
execute implementation plan as part of the core team leading up to ERS convention in September
participate in virtual conventions including ERS (if timeline feasible)
Requirements
This will require an individual who is a self-starter and confident presenter. We are looking for a mix of analytical skills and ability to think creatively. Experience in pharmaceutical industry not required. Experience with communicating complex content through digital channels is a big plus.
Sanofi Genzyme
Cambridge, MA
As the specialty care global business unit of Sanofi, we are focused on rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. More than 30 years since we began, we remain just as committed to and passionate about advancing therapies that offer hope to patients and families.
Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology. In 2018, with the acquisitions of Bioverativ and Ablynx, we further expanded our focus to include rare blood disorders, bringing deep expertise in hematology.
Our ambition is to be the industry leader in specialty care. We currently provide more than 25 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.
Driven by our commitment to patients, we strive to develop strong relationships with our patient communities, listening to their perspectives so that we can truly understand their needs. These collaborations continue to guide and motivate us as we work to push the boundaries of medicine and technology to develop new and better therapies where none existed before.
-
IndustryBiopharmaceuticals
-
No. of Employees14,000+
-
Website
-
Jobs Posted207
